银屑病的生物制剂治疗研究进展

Research progress on the biological agents in treatment of psoriasis

银屑病是一种常见的以表皮过度增生为特征的慢性复发性非感染性炎症性的皮肤病;也是一种在多基因遗传背景下,由多种致病因子刺激机体免疫系统而引起的由T细胞介导为主的免疫相关性自身免疫紊乱性皮肤病。该病病因复杂,病程较长,且易反复发作。虽治疗药物繁多,疗法多样,但疗效并不能确定,目前仍以改善患者症状为主。从生物制剂治疗的角度,对其临床相关的研究进展进行系统归纳总结,以期为其临床治疗提供参考。

Psoriasis is a common skin disease with chronic, recurrent, noninfectious, and inflammatory phenomenon, characterized by skin excessive proliferation. In the polygenic inheritance background, it is also an immune associated autoimmune disorders skin disease caused by T cell-mediated, which is caused by a variety of pathogenic factors to stimulate the body＇s immune system. The causes of the disease are complex. The course of the disease is long, and the recurrent attacks of the disease are easy. Therapeutic drugs are various and the treatment is diverse, but the curative effect is not sure. Therefore the treatment is still given priority to improve the symptoms of the patients. This paper, respectively from the perspective of biological drugs, systematically summarizes the research progress in the biological agents for the treatment of psoriasis, in order to lay the foundation for the clinical treatment.